380 related articles for article (PubMed ID: 10023446)
1. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
[TBL] [Abstract][Full Text] [Related]
3. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy.
Duan L; Zhu M; Ozaki I; Zhang H; Wei DL; Pomerantz RJ
Gene Ther; 1997 Jun; 4(6):533-43. PubMed ID: 9231069
[TBL] [Abstract][Full Text] [Related]
4. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
5. Regulation of expression of human immunodeficiency virus.
Pavlakis GN; Felber BK
New Biol; 1990 Jan; 2(1):20-31. PubMed ID: 2078551
[TBL] [Abstract][Full Text] [Related]
6. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication.
Caputo A; Rossi C; Bozzini R; Betti M; Grossi MP; Barbanti-Brodano G; Balboni PG
Gene Ther; 1997 Apr; 4(4):288-95. PubMed ID: 9176513
[TBL] [Abstract][Full Text] [Related]
7. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector.
Cara A; Rybak SM; Newton DL; Crowley R; Rottschafer SE; Reitz MS; Gusella GL
Gene Ther; 1998 Jan; 5(1):65-75. PubMed ID: 9536266
[TBL] [Abstract][Full Text] [Related]
9. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1.
Chang HK; Gendelman R; Lisziewicz J; Gallo RC; Ensoli B
Gene Ther; 1994 May; 1(3):208-16. PubMed ID: 7584083
[TBL] [Abstract][Full Text] [Related]
10. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.
Li MJ; Kim J; Li S; Zaia J; Yee JK; Anderson J; Akkina R; Rossi JJ
Mol Ther; 2005 Nov; 12(5):900-9. PubMed ID: 16115802
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
Lee SW; Gallardo HF; Gilboa E; Smith C
J Virol; 1994 Dec; 68(12):8254-64. PubMed ID: 7966618
[TBL] [Abstract][Full Text] [Related]
12. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.
Li M; Li H; Rossi JJ
Ann N Y Acad Sci; 2006 Oct; 1082():172-9. PubMed ID: 17145937
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
14. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells.
Lee TC; Sullenger BA; Gallardo HF; Ungers GE; Gilboa E
New Biol; 1992 Jan; 4(1):66-74. PubMed ID: 1536832
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
17. Structural RNA mimetics: N3'-->P5' phosphoramidate DNA analogs of HIV-1 RRE and TAR RNA form A-type helices that bind specifically to Rev and Tat-related peptides.
Rigl CT; Lloyd DH; Tsou DS; Gryaznov SM; Wilson WD
Biochemistry; 1997 Jan; 36(3):650-9. PubMed ID: 9012680
[TBL] [Abstract][Full Text] [Related]
18. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells.
Liu J; Woffendin C; Yang ZY; Nabel GJ
Gene Ther; 1994 Jan; 1(1):32-7. PubMed ID: 7584057
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
20. Potent knock down of HIV-1 replication by targeting HIV-1 Tat/Rev RNA sequences synergistically with catalytic RNA and DNA.
Sood V; Unwalla H; Gupta N; Chakraborti S; Banerjea AC
AIDS; 2007 Jan; 21(1):31-40. PubMed ID: 17148965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
